Product Highlight - Fosphenytoin sodium (Aurantin)

31 Aug 2023
Product Highlight - Fosphenytoin sodium (Aurantin)
  • Antiepileptic drug of hydantoin derivative makes it suitable for treatment of status epilepticus.1
  •  Fosphenytoin Sodium (Aurantin) is generally better tolerated than phenytoin.2
  •  Fosphenytoin Sodium (Aurantin) can be administered faster than phenytoin.3
  •  Fosphenytoin Sodium (Aurantin) as a pro drug which were converted into an active form of phenytoin once injected has greater ease of infusion (less pain, fewer disruptions and shorter infusion period) compared to phenytoin.4

 

 
References:
1.) Fosphenytoin Sodium (Aurantin) Product Insert Version 7.2: 03 February 2022.
2.) Glauser T, et al. Epilepsy Curr 2016;16(1):48-61.
3.) De Toledo JC, Ramsay RE. Drug Saf 2000;22(6):459-466.
4.) Thomson A. Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes. Core evidence, 1(1), 65–75 (2005).
5.) Dalziel SR, et al. Lancet 2019;6736(19):30722-30726.

 

19/F-20/F 8 Rockwell Building,
Hidalgo Drive Rockwell Center, Poblacion,
Makati City, 1210 Metro Manila Philippines
GCMA Code: PP-UNP-PHL-0345
May 2023 for Healthcare Professionals Only


Related MIMS Drugs